Edgewise Therapeutics stock falls after FDA deems data insufficient for accelerated approval

Edgewise Therapeutics (NASDAQ:EWTX) shares declined 7.2% after the FDA deemed its CANYON trial data for sevasemten in Becker muscular dystrophy insufficient for accelerated approval, indicating a traditional pathway is required. The agency supports the ongoing GRAND CANYON pivotal trial, with topline results expected in Q4 2026. Concurrently, Edgewise reported encouraging Phase 2 data from its LYNX and FOX trials for Duchenne muscular dystrophy, identifying an optimal dose for planned Phase 3 studies in 2026, signaling continued pipeline progress despite the Becker MD regulatory setback.

Analysis

Edgewise Therapeutics (EWTX) experienced a significant regulatory setback, reflected in a 7.2% stock decline, after the U.S. FDA determined its CANYON trial data was insufficient for accelerated approval of sevasemten for Becker muscular dystrophy (BMD). This decision effectively removes a near-term catalyst and pushes the potential commercialization timeline out substantially, as the company must now rely on the traditional approval pathway. The FDA's guidance points toward the ongoing GRAND CANYON pivotal trial as the primary basis for registration, with topline data not anticipated until the fourth quarter of 2026. While this introduces considerable delay and uncertainty for the BMD program, the company's pipeline shows progress elsewhere. Edgewise reported encouraging topline data from its Phase 2 Duchenne muscular dystrophy (DMD) trials, LYNX and FOX, successfully identifying an optimal 10mg dose. The company plans to engage with the FDA in Q4 2025 to design a Phase 3 study for its DMD candidate, with trial initiation planned for 2026. This development in the DMD program provides a partial offset to the BMD news, shifting the focus to a different, albeit also long-term, value driver within the company's portfolio.

Key Decisions for Investors

• Investors must recalibrate valuation models for EWTX, as the revenue timeline for sevasemten in Becker muscular dystrophy is now delayed until at least 2027, pending positive GRAND CANYON trial results in late 2026.
• The focus for potential value creation now shifts to the Duchenne muscular dystrophy program; key upcoming catalysts to monitor are the FDA meeting in Q4 2025 and the initiation of the pivotal trial in 2026.
• Given the negative regulatory news for the lead program, investors should anticipate heightened stock volatility and a requirement for a longer-term investment horizon, as near-term catalysts have been significantly diminished.